NASDAQ · Biotechnology
QURE (QURE) Stock
$43.63
+3.41%
NASDAQ: QURE
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Uniqure Insider Sold Shares Worth $952,051, According to a Recent SEC Filing
MT Newswires · Jul 7, 2026
Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing
MT Newswires · Jul 2, 2026
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
Zacks · Jul 1, 2026
XBI Ignored The Market's Downturn
Trefis · Jun 29, 2026
UniQure Closes $259 Million Stock Offering
MT Newswires · Jun 25, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held1.29%
Institutions Held90.20%
Institutions Float Held91.38%
Peer Comparison
About QURE
QURE is led by CEO Matthew Craig Kapusta, employs 209 people, headquartered in US, publicly traded since 2014.
QURE stock trades at $43.63 with a market capitalization of $3.03B. The stock is valued at a price-to-earnings (P/E) ratio of -11.42, price-to-book of 8.72, price-to-sales of 96.97. Over the past 52 weeks the stock has ranged between $8.73 and $71.50, and currently trades 39.0% below its 52-week high.
On profitability, QURE generates a return on equity (ROE) of -228.24%, return on capital employed of -94.47%, an operating margin of -10.57%, a net profit margin of -11.54%.